[1] Yu Xiaoyong, Yang Shaoning, Zhang Xiaofeng,.Progress in Diagnosis and Treatment of Cardiorenal Syndrome with Traditional Chinese and Western Medicine [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2020, (01): 43-47. [doi: 10.13424/j.cnki.jsctcm.2020.01.012]
Progress in Diagnosis and Treatment of Cardiorenal Syndrome with Traditional Chinese and Western Medicine
- Article number:
- 2096-1340(2020)01-0043-05
- Keywords:
- cardiorenal syndrome; mechanism; biomarker; understanding of traditional Chinese medicine; clinical effect
- ZTFLH:
- R2-09
- Code:
- B
- Abstract:
- Cardiorenal syndrome is a complex clinical syndrome with the interaction of cardiac and renal insufficiency, including different pathophysiological diseases of heart and kidney, which are the clinical risk factors of each other.In recent years, the incidence of this disease has been increasing year by year, but its therapeutic effect is not ideal, and the prognosis is poor. This article starts from the classification, prediction indexes, pathogenesis and treatment of cardiorenal syndrome, and summarizes the understanding of traditional Chinese medicine on cardiorenal syndrome and the related clinical research in recent years, so as to provide more useful reference for its clinical diagnosis and treatment.
References:
[1]Schefold J C, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management[ J] . Nat Rev Nephrol, 2016, 12( 10) :610 -623.
[2]Adams K J, Fonarow G C, Emerman C L, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry ( ADHERE) [ J] . Am Heart J, 2005,149( 2) :209 -216.
[3]McAlister F A, Ezekowitz J, Tonelli M, et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study[ J] . Circulation, 2004,109( 8) :1004 -1009.
[4]Gansevoort R T, Correa - Rotter R, Hemmelgarn B R, etal. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention[ J] . Lancet, 2013,382( 9889) :339 -352.
[5]Sud M, Tangri N, Pintilie M, et al. ESRD and death after heart failure in CKD[ J] . J Am Soc Nephrol, 2015, 26( 3) :715 -722.
[6]Ronco C, Di Lullo L. Cardiorenal Syndrome in Western Countries: Epidemiology, Diagnosis and Management Approaches[ J] . Kidney Dis ( Basel) , 2017, 2 ( 4) : 151-163.
[7]Ronco C, McCullough P, Anker S D, et al. Cardio - renal syndromes: report from the consensus conference of the acute dialysis quality initiative [ J] . Eur Heart J,2010,31( 6) :703 -711.
[8]Takahama H, Nishikimi T, Takashio S, et al. Change in the NT - proBNP/ Mature BNP Molar Ratio Precedes Worsening Renal Function in Patients With Acute Heart Failure: A Novel Predictor Candidate for Cardiorenal Syndrome[ J] . J Am Heart Assoc, 2019,8( 17) : e11468.
[9]Sheng X, Lin L, Guo F, et al. Copeptin level in the early prediction of cardiorenal syndrome in rats[ J] . Exp Ther Med, 2018,16( 2) :937 -944.
[10]Schefold J C, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management[ J] . Nat Rev Nephrol, 2016, 12( 10) :610 -623.
[11]Virzi G M, Breglia A, Brocca A, et al. Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with Acute Heart Failure with and without Cardiorenal Syndrome Type 1 [ J] . Cardiorenal Med, 2018,8( 4) :321 -331.
[12]Linhart C, Ulrich C, Greinert D, et al. Systemic inflammation in acute cardiorenal syndrome: an observational pilot study[ J] . ESC Heart Fail, 2018,5( 5) :920 -930.
[13]Volpe M, Carnovali M, Mastromarino V. The natriureticpeptides system in the pathophysiology of heart failure:from molecular basis to treatment[ J] . Clin Sci ( Lond) ,2016,130( 2) :57 -77.
[14]Clementi A, Virzi G M, Battaglia G G, et al. Neurohormonal, Endocrine, and Immune Dysregulation and Inflammation in Cardiorenal Syndrome[ J] . Cardiorenal Med,2019,9( 5) :265 -273.
[15]Zannad F, Rossignol P. Cardiorenal Syndrome Revisited[ J] . Circulation, 2018,138( 9) :929 -944.
[16]李鹤,刘亚洋.益气强心方对 1型心肾综合征病人心肾功能的影响 [J].中西医结合心脑血管病杂志,2019,17(9):1390-1391.
[17]张群生.温阳益气活血方辅治Ⅱ型心肾综合征对心功能及肾功能影响[J].实用中医药杂志,2019,35(8):999-1000.
[18]冯伟,张晶,方芳.益气温阳活血利水方干预心肾综合征患者心肾功能的临床研究[J].中国循证心血管医学杂志,2019,11(9):1096-1098.
[19]王慧敏,吴英智,韦震鸣,等.真武汤治疗Ⅱ型及Ⅳ型心肾综合征的临床研究[J].实用医学杂志,2018,34(13):2255-2259.
[20]王海霞,牛燕运.温阳益气活血法对Ⅱ型心肾综合征病人心功能及肾功能的影响[J].中西医结合心脑血管病杂志,2018,16(17):2537-2539.
[21]张秀荣,薛一涛.真武汤合保元汤对 2型心肾综合征阳气亏虚证兼血瘀证心肾功能的影响[J].中国实验方剂学杂志,2018,24(9):202-207.
Memo
基金项目：陕西省科技厅社发攻关一般项目（２０１７ＳＦ－２９８）；陕西省中医药管理局资助项目（１５－ＬＣ０２４）